RANKL Antibody for Acute Charcot Neuro-osteoarthropathy

• Status: Active, not recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This study's goal was to determine how denosumab 60 mg, combined with total contact casting and restricted weightbearing status, would affect the treatment of acute CN with CKD.

METHODS Participants in the research were those who visited the outpatient foot clinic at PGIMER, CHD in India. During the study period, 446 persons with CN were identified, 102 of whom met the criteria for the first screening, and 60 of whom were ultimately enrolled in the study.

Aim: To assess the clinico-radiological remission of Acute Charcot-neuroarthropathy in patients of CKD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research

Criteria

Inclusion Criteria:

Diabetes Active Charcot neuroarthropathy of foot Chronic Kidney disease defined as eGFR<60 ml/min/m2 and/or Urine protein >300 mg/day Presence of all

Exclusion Criteria:

Active Pedal ulcer Active malignancy Hypocalcemia Primary Hyperparathyroidism Pregnancy and Breast Feeding